Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 6/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10125374 | 1.00 | VDR (1.00) | VDR | |
| SCHEMBL13090316 | 1.00 | VDR (1.00) | VDR | |
| SCHEMBL10125232 | 0.94 | VDR (0.88) | VDR | |
| SCHEMBL10152497 | 0.90 | VDR (0.81) | VDR | |
| SCHEMBL10125508 | 0.88 | VDR (0.79) | VDR | |
| SCHEMBL10125254 | 0.88 | VDR (0.79) | VDR | |
| SCHEMBL4168474 | 0.88 | VDR (0.78) | VDR | |
| SCHEMBL19288068 | 0.86 | VDR (0.77) | VDR | |
| SCHEMBL10125228 | 0.84 | VDR (0.77) | VDR | |
| SCHEMBL18059298 | 0.84 | VDR (0.77) | VDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117901806-A | Intelligent self-locking system based on vehicle body controller | 苏州天浩汽车科技股份有限公司 | 2024-04-19 | — | — | CN | claimed |
| EP-4735431-A2 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260042788-A1 | STAT6 COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4681774-A2 | KHK INHIBITORS | Gilead Sciences, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20260014147-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4674484-A2 | THIENOPYRROLE COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20260001893-A1 | SMALL MOLECULE MODULATORS OF STAT6 | GILEAD SCIENCES INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12503454-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| EP-4313967-B1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20220323464-A1 | COMPOSITION, FORMULATIONS AND METHODS OF MAKING AND USING BOTANICALS AND NATURAL COMPOUNDS FOR THE PROMOTION OF HEALTHY BRAIN AGING | THE BRAIN HEALTH PROJECT, LLC | 2022-10-13 | — | — | US | disclosed |
| WO-2022212194-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| EP-4058144-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| WO-2022173722-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| CN-114728168-A | Triazolecarbamate pyridylsulfonamides as LPA receptor antagonists and their use | 吉利德科学公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2022140326-A1 | SUBSTITUTED INDOLE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140325-A1 | 6-SUBSTITUTED INDOLE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20220149826-A1 | AMPLITUDE MODULATION CIRCUIT AND SEMICONDUCTOR INTEGRATED CIRCUIT FOR OPTICAL COMMUNICATION SYSTEM | SUMITOMO ELECTRIC INDUSTRIES, LTD. (JP) | 2022-05-12 | — | — | US | disclosed |
| US-20220117979-A1 | Composition, Formulations and Methods of Making and Using Botanicals and Natural Compounds for the Promotion of Healthy Brain Aging | THE BRAIN HEALTH PROJECT LLC (US) | 2022-04-21 | — | — | US | disclosed |
| US-11288869-B2 | Information processing device, and information processing method | SONY CORPORATION (JP) | 2022-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042788-A1 | STAT6 COMPOUNDS | STAT6, IL6ST, NFATC1 | VDR 1168/4885 |
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | VDR 2582/4885 |
| US-20260001893-A1 | SMALL MOLECULE MODULATORS OF STAT6 | STAT6, NCOR1, NCOR2 | VDR 477/4885 |
| US-12503454-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | VDR 475/4885 |
| US-20260014147-A1 | STAT6 DEGRADERS | STAT6, NCOR1, CBR1 | VDR 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.